There is 1 paper on time in target systolic blood pressure range in aging research: 1 observational study in people.
1 paper studies it1 more mentions it6 findings
1 new paper in 30 daysSee all 2 papers on time in target systolic blood pressure range
“This association was primarily driven by a lower risk of HFH (P=0.007)”
- Humans1
Interventions
4Finerenone
upin humans1
1 study
Finerenone
upin humans1
Finerenone increases time in target systolic blood pressure range in humans (Heart failure with LVEF ≥40%; target systolic blood pressure 110–<130 mmHg) (4% (95% CI 2 to 5%)).
“4% (2 to 5%) with finerenone.”
Human trialHeart failure with LVEF ≥40%; target systolic blood pressure 110–<130 mmHgfirst year
ESC Congress 2026 abstract
Dapagliflozin
upin humans1
1 study
Dapagliflozin
upin humans1
Dapagliflozin increases time in target systolic blood pressure range in humans (Heart failure with LVEF >40%; target systolic blood pressure 110–<130 mmHg) (2% (95% CI 0 to 4%)).
“2% (0 to 4%) with dapagliflozin”
Human trialHeart failure with LVEF >40%; target systolic blood pressure 110–<130 mmHgfirst year
ESC Congress 2026 abstract
Sacubitril + valsartan
upin humans1
1 study
Sacubitril + valsartan
upin humans1
Sacubitril + valsartan increases time in target systolic blood pressure range in humans (7% (95% CI 5 to 9%)).
“7% (5 to 9%) with sacubitril/valsartan”
Human trialHeart failure with LVEF ≥45%; compared with valsartan; target systolic blood pressure 110–<130 mmHgfirst year
ESC Congress 2026 abstract
Spironolactone
upin humans1
1 study
Spironolactone
upin humans1
Spironolactone increases time in target systolic blood pressure range in humans (Heart failure with LVEF ≥45%; target systolic blood pressure 110–<130 mmHg) (3% (95% CI −1 to 7%)).
“Randomization to active therapies increased the percentage of TIR across trials, by 3% (95%CI −1 to 7%) with spironolactone”
Human trialHeart failure with LVEF ≥45%; target systolic blood pressure 110–<130 mmHgfirst year
ESC Congress 2026 abstract
Effects
1Cardiovascular and all-cause mortality
no changein humans1
1 study
Cardiovascular and all-cause mortality
no changein humans1
Time in target systolic blood pressure range was not clearly linked with cardiovascular and all-cause mortality in humans (Heart failure with mildly reduced or preserved ejection fraction).
“no significant associations were observed with CV death or all-cause death.”
HumansHeart failure with mildly reduced or preserved ejection fractionTime in target range assessed during the first year after randomization47% mensn = 18,823
ESC Congress 2026 abstract
Associations
1Heart failure hospitalization
downin humans1
1 study
Heart failure hospitalization
downin humans1
Time in target systolic blood pressure range is associated with heart failure hospitalization in humans.
“This association was primarily driven by a lower risk of HFH (P=0.007)”
HumansHeart failure with mildly reduced or preserved ejection fraction; target systolic blood pressure 110–<130 mmHgTime in target range assessed during the first year after randomization47% mensn = 18,823
ESC Congress 2026 abstract